ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1367

Impact of Ixekizumab on Work Productivity in Non-Radiographic Axial Spondyloarthritis Patients: Results from the COAST-X Trial at 52 Weeks

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1272

Impact of Remission and Low Disease Activity Status on Hospitalizations Among SLE Patients from the GLADEL Latin American Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 0992

Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: PP01

Impacting Change Through Facilitation and Advocacy for Lupus

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 1151

Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia

Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1142

Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1145

Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1371

Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1341

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: PP07

Improving Communication with My Physician Drastically Improved My Health

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 1124

Improving Documentation Rates of Non-Pharmacologic Therapies for Knee Osteoarthritis

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1184

In a Prospective RA Cohort, Higher Baseline Disease Activity Is an Independent Predictor of Decline in Left Ventricular Diastolic Function

RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

9:00AM-11:00AM: Abstract Number: 1436

Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study

Vasculitis – ANCA-Associated Poster

9:00AM-11:00AM: Abstract Number: 1182

Increased Prevalence of Carotid Atherosclerosis in Postmenopausal Women with Rheumatoid Arthritis: A Case Control Study

RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

9:00AM-11:00AM: Abstract Number: 1220

Increased Serum Levels of Circulating Vimentin and Citrullinated Vimentin Are Differently Regulated by Tocilizumab and Methotrexate Monotherapies in Rheumatoid Arthritis

RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].